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Mechanisms of death among patients who died within IS h of
enrollment in the Thrombolysis in Myocardial Infarction Phase 11
(TIMI 11) study were analyzed . 00,339 patients enrolled, 32 died
within the 1st 4 h and 31 died within the subsequent 14 h . Thirteen
of the 63 patients had shock at enrollment ; 22 had advanced
hemodynamic compromise without shock and 28 initially had
minimal to no compromise .
Prior infarction was present in 16 patients (25%) . Pump
failure was responsible for 39 early deaths (62%), ventricular
rupture for 10 (16%), arrhythmia for S 113%) and complications
of therapy Bar 6 (10%r). Nine of 720 patients randomized to
Thrombolytic therapy for patients with acute myocardial
infarction has greatly improved the prognosis associated
with this syndrome (1-4). The mortality rate among patients
enrolled in trials of thrombolytic therapy is currently be-
tween 5% and 9%
(4
.5) . As further advances in the treatment
of myocardial infarction occur, any further decline in the
already tow mortality will become increasingly difficult to
establish . To be most effective, future refinements in reper-
fusion therapy will need to be targeted toward the clinical
presentations preceding, and the mechar,isnts responsible
for, the majority of deaths
. Previous studies (6,7)
indicated
that most of the deaths after thrombolytic therapy occur
soon after patient presentation and suggested that throm-
bolytic therapy may not prevent death during the Lt day
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immediate intravenous beta-adrenergic blacking agent therapy
had an early death compared with 6 of 714 assigned to deferred
bom•h lorker therapy .
Thus, mortality is highest in the early hours after myocardial
infarction, even in patients treated with thromboytic therapy and
is most frequently due to pump failure
.
T-
.-.c
results imply that
efforts to reduce mortality during this critical time period should
be directed at prevention, limitation or Inflation of early pump
failure .
(J
Am Call Cordial 1992
;1"129-35)
after infarction. If patients likely to die during this period
could be identified with reasonable precision, adjunctive or
more aggressive therapy might be selected promptly and
applied with a more beneficial outcome . This study was
therefore undertaken to analyze early deaths among patients
receiving intravenous recombinant tissue-type plasminogen
activator (rt-PA) in the Thrombolysis in Myocardial Infarc-
tion Phase 11 (TIMI 11) study .
Methods
Study protocol. The design of the trial has been reported
previously (8) .
The study protocol was approved by the
itstional Rcv(ew Board of each participating center, and
all participating subjects gave informed consent
. Briefly, 24
clinical centers participated in the study . Patients were
eligible for enrollment if they fulfilled the following criteria :
I) age s76 years, 2) chest discomfort suggestive of acute
myocardial ischemia lasting a30 min, 3) ST segment ele-
vation a0.1 mV in two electrically contiguous leads, and
4) presentation within 4 h after the onset of chest pain
.
Patients were excluded from the trial for a history of stroke
or cerebrovascular disease, systolic blood pressure
>180 mm Hg or diastolic blood pressure >110 mm Hg, a
bleeding disorder, a surgical procedure within the preceding
o735-1097NL55-
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2 weeks, recent card opulmonary, resusc tat on, percutane-
ous translum nal coronary ang oplasty or severe trauma
w th n the prev ous 6 months, pr or coronary artery bypass
surgery or prosthet c heart valve replacement, left bundle
branch block, d lated card omyopathy or other ser ous ll-
ness.
Intravenous rt-PA was adm n stered over a per od of 6 h .
For 520 pat ents the ntended dosage was 150 ITS, and for the
subsequent 2,819 pat ents, the ntended dosage was 100 mg.
Hepar n was g ven as an ntravenous bolus nject on of
5,000 U followed by an nfus on of 1,000 Ulh.
Beta-adrenerg c block ng agent el g b l ty . Pat ents were
el g ble for a random zed substudy of
mmed ate ntravenous
compared w th oral beta-adrenergc block ng agent therapy
(TIMI IIB) f they were not alreads rece v ng a beta-blocker,
verapam l ord
lt
azem and d d not have a contra
nd cat on to
beta-adrenerg
c blockade . Intravenous metoprolol was ad-
m n stered as a ser es of three bolus doses of 5 mg separated
by 2 m n and followed by oral beta-blocker therapy ; deferred
oral beta-blocker therapy began 6 days after study entry (9) .
Class fcat on of death and cln cal character st
cs
. All
deaths were reported to the Coord nat ng Center and were
rev ewed by a Mortal ty and Morb d ty Class f cat on Com-
m ttee, wh ch cons sted of persons who were not assoc ated
w th cl n cal centers and who had no knowledge of the
pat ents' treatment ass
gnments
. Mechan sms of death clas-
s f ed by the comm ttee ncluded I) ventr cular rupture, 2)
pump fa lure, and 3) arrhythm a . The Mortal ty and Morb d-
ty Class
f cat on Comm ttee could
dent
fy any of all of these
mechan sms as contr butors to a pat ent's death . Ass gnment
of the pr mary mechan sm of card ac death was based on the
degree to wh ch the mechan sm would be rrevers ble n a
card ac care sett ng .
In th s analys s, ventr cular rupture was cons dered the
pr mary mechan sm of death whenever ev
dence (d rect
v sual zat on of the heart or sudden card ac death nclud ng
electromechan cal d ssoc at on n the sett ng of cont nuously
mon tored and normal blood pressure and electr cal rhythm)
for ventr cular rupture was present . Pump fa lure was con-
s dered the pr mary mechan sm for pat ents w th progress ve
hypotens on, no extracard ac et ology and no ev dence of
card ac rupture
. Arrhythm a was cons dered the pr mary
mechan sm when t was observed n the absence of both
ventr
cular rupture and pump fa lure . Fatal compl cat ons of
therapy, such as hemorrhag c or operat ve compl
cat
ons,
were also class fed .
At the r me of protocol derelopment, t was dec ded to
character ze pat
ents as
"not lrnv
r sk" f they had one of
the
follow ng ct n cal character st cs: age ?70 years, pr or myo-
card al nfarct on, anter or myocard al nfarct on, rates over
>113 of the lung felds, hypotens
on w
th s
nus tachycard a.
atr al f br llat on or flutter. pulmonary edema or card
ogen c
shock . Shock was cons dered present
f the systol c blood
pressure was
m85
mm Hg w th ev dence of t ssue hypoper-
fus
on and was nterpreted on n t al evaluat on to be a
consequence of left ventr cular dysfunct on
. In the TIMI ll
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Table 1
.
Deathsl1,000 Pat ent-Hours Accord ng to T me From
Study Entry
No. at
R sk at
T me From Study Start of DeathslI,IIO
Entry Noo or Deaths Per od Pat ent-Hours
54 h 32 3,339 2.41
>4ardzIsh 31 3 .3w
0.67
>10handv
tdays
79 3 .276
0 .08
>I4and=4'--day,
23 1 .196
001
Mortal ofOperatlons, normal zat on of ST segment abnor-
mal
t es was defned as "return of ST segments to or qu te
close to basel ne" on cl n cal center staff observat on.
In plann ng th s analys s, pat ents were cons dered to
have hemodvnam
c comprom
se n the absence
of
shock
f
one of thefllon' ng character st cs was present : pulmonary
edema on chest rad ography . rates over >113 of the lung
f elds, hypotens on (systol c blood pressure <100 mm Hg)
w th s nus tachycard a (s nus rate >100 beats/m n) or sec-
ond- or th rd-degree atr oventr cular black.
Earl' death was cons dered to have occurred between the
t me of study enrollment and the beg nn ng of the t me durng
wh ch randomly ass gned nvas ve strategy (that s, catheter-
zat on and, f feas ble, coronary ang oplasty) was to have
begun (18 h after study entry) . Because the major ty of
occluded nfarct vessels that ach eve reperfus on do so
w th n the f rst few hours after treatment w th a thrombolyt c
drug (10,11) . the group w th early death was further d chot-
om
zed at 4 h after enrollment
.
Stat st
cal analys s
. Probab l
ty values for percentages
were calculated by us ng standard ch -square tests (12). To
adjust for mult ple test ng, a probab l ty value between 0.01
and 0 .001 for two-s ded tests has been spec fed as prov d ng
some ev dence of d fferences, and probab l ty values <0 .1101
have been spec f ed as prov d ng strong ev dence of d ffer-
ences . To est mate the rates at wh ch deaths occurred, a
p ecew se exponent al surv val model (13) was developed at
the t me of the analys s. It was assumed that mortal ty
rema ned constant w th n the ntervals 0 to 4 h, 4 to 18 h, 18 h
to 14 days and 14 days to 42 days after study entry . W th n
each nterval, the rate was est mated by the method of
max mal l kel hood. The est mated death rate was calculated
as the number of deaths n the nterval d v ded by the total
t me of pat ent follow-up n the nterval . Relat ve r sks were
est
mated w
th standard methods for proport ons, and 99%
confdence ntervals for the relat ve r sks were est mated by
us ng a Taylor ser es approx mat on (12,13). All stat st cal
analyses were conducted w th the Stat st cal Analys s Sys-
tem ISAS) software package (14) and the TIMI 11 analys s
f le of September 1990 .
Results
Study pat ents (Tables I and 21. A total of 3,339 pat ents
were enrolled n the study: 165 (4.9%) deaths occurred
3ACC Vol
. 19
. No .6
May 1992:1129-35
Table 2
. Actual r-PA Dose Rece ved Accord ng to
Length of Surv val
'p 10.001 . n-PA - recomb nard t ssue-type plasm nogen act vator,
w th n the 1st 6 weeks . S xty-three pat ents (1 .9%) d ed
w th n the 1st 1S h after enrollment and form the bas s of the
present report . Four of the 63 pat ents underwent coronary
arter ography, nclud
ng 3 who underwent emergency ang o-
plasty and 2 who underwent emergency bypass surgery .
Mortal ty (deaths/1,000 pat ent-hours) accord ng to t me
from study entry s shown n Table 1 .
Th
rty-two (50%)
of the 63 early deaths occurred w th n
the lot 4 h and 41 (65%) occurred before the prescr bed 6-h
nfus on of rt-PA could be completed
. F
fteen (47%) of the
32 pat ents who d ed w th n 4 h rece ved <80 mg of n-PA
compared w th 4 (13%) of 31 pat ents who d ed between
4 and 18 h after study entry and 22 (0.6%) of 3,276 pat ents
who surv
val for 18 h (Table 2) and rece ved <80 mg of
rt-PA. Among pat ents who d ed w
th
n the 1st 4 h . the
reasons for premature term nat on of the nfus on were death
or card ac arrest n 26 pat ents (81%), hypotens on n 3 (9%)
and bleed
ng or m scellaneous compl cat ons n 2 (6%). One
pat ent (3%) rece ved the full dose
. Among 31 pat ents who
d ed between 4 and 18 h after study entry, the nfus
on was
nterrupted n 15 (48%) because of death or card
ac arrest
n 9 pat ents (29%), card ogen e shock n 2 (6%), bleed ng n
1 (3%), nvas ve procedures n 2 (6%) and unreported rea-
sons n I pat ent (3%) . S xteen pat ents (52%) who d ed n
th s nterval rece ved the full dose . The n-PA nfus on was
nterrupted n 92 pat ents (3%) surv
v
ng >18 h
. The most
frequent reasons were bleed ng n 37 pat ents (1%), techn cal
problems w th the nfus on n 26 (1%) and m scellaneous
reasons (
nclud
ng card
ovascular, neurolog c and other
compl cat ons) n 22 (1%). Reasons for nterrupt on of the
nfus on were not ava lable n 7 pat ents (0.2%) who surv ved
>18 h .
Clncal character st cs ITable 3). At the t
me of study
entry, 57 (90%) of the pat ents w th early death were n the
"not low rsk" category, 43 (68%) had anter or wall myo-
card al nfarct on, 22 (35%) had ev dence of hemodynam c
comprom
se w
thout eard ogen
c shock and 13 (21%) were n
card ogen c shock. The mean tme from the onset of symp-
toms to the n t at on of n-PA nfus on was 2 .7 ± 0 .8 h n
KLEIb1AN ET AL
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pat ents who d
ed w th n 18 h compared w th 2 .6 ± 0 .8 b n
pat
ents who surv ved >18 h (p = 0.30) .
There were 13 early deaths (26%) among 50 pat ents w th
shock . 22 (5 .9%) among 375 pat
ents w th hemodynam c
comprom se but w thout shock and 28 (1%) among 2
.914
pat ents present ng w th l ttle or no hemodynam c compro-
m se . The
nd
v
dual characterst cs assoc ated w th the
h ghest frequency of early death were shock
n 13 (26%) of
50, rad
ograph c ev dence of pulmonary edema n 4 (11 .5%)
of 34, rules over >113 of the lung f elds on n t al exam nat on
n 13 (9.5%) of 134, hypotens on w
th s nus tachycard a n 17
(9%) of 187 and a h story of per pheral vascular d sease n 9
(R%) of 115
. The character st cs of pat ents who d ed w th n
4 h of study entry were s m lar to those of pat ents who d ed
between 4 and 18 h after study entry
.
Cl n cal response to rt-PA nfus on (Table 4) . Rel ef of
chest pa n, normal zat on of ST segment dev at on and
ncrease
n blood pressure were less common dur ng n-PA
nfus on among pat ents who d
ed early than among those
who surv ved the 1st 18 h; worsen ng of chest pa n. exacer-
bat on of ST segment dev at on and decrease n blood
pressure were more common n the group who d ed early.
Among the 44 pat ents who d
ed early and who had a
reported decrease n blood pressure, the decrease pre-
ceded death by s30 m n n I pat ent (2%), by >30 m n but
w th n 2 h n 20 pat ents (45%) and by >2 h n 23 pat ents
(52%).
Mortal
ty and Morb
d
ty Classfcat on Commttee class f-
cat ons of causes and
mechan sm of death (Tables 5 and 6) .
Pump fa lure was the most common mechan sm of early
death, account ng for 62% of cases (Table 5) . Ventrcular
rupture accounted for 16% and arrhythm a 13%. Compl ca-
t ons of therapy result ng
n death w
th
n 18 h of study entry
ncluded three gastro ntest nal hemorrhages and two hemor-
rhages nto soft t ssue compartments (the med ast num and
the retroper tuneum) . One pat ent d ed w th n 18 h of study
entry of compl catons of coronary artery bypass graft sur-
gery (fa
lure to wean from card opulmonary bypass followed
by hemorrhage at the s te of ventrcular ass st dev
ce nser-
t on)
.
In 28 of the 63 pat ents who d ed early, the per card
um
was exam ned e ther at autopsy (27 pat ents) or at operat on
(I pat ent). Ventr cular rupture was d agnosed n seven
(25%) of these pat ents . In three pat ents whose percard
um
was r: : actually exam ned, ventrcular rupture was dent -
fed on the bas s of cl n cal events. There were no d fferences
n mechan sm of death among pat ents who d ed <4 h or
between 4 and 18 h .
The mechan sm of death accord ng to hemodynam c
status at study entry s shown
n Table 6
. Pump fa lure
accounted for >80% of deaths among pat ents w th hemo-
dynam c comprom se and card ogen c shock and for nearly
39% of the deaths n pat ents w thout major hemodynam c
comprom se. Ventr cular rupture was the mechan sm of
death for a 1?rger proport on of the pat ents w thout hemo-
dynam c comprom se . There was l ttle d fference n the
n-PA Dose
Rece ved
Img)
Length of Surv val
<_4 h
In (911
4-18 h
In 19)l
>18 h
In (7)I
<40 3(9 .41
11321 22(0.11
40-59 3(9.41 1(33) 410.1)
60-79 9)28.1) 2(6 .4) 16(0.51
80-99 1300.61 10132.31 5111 .61
100 2 116 .2) 14 (45 .2) 2 .698 (92.4)
101-149 2 (6.2) 1 (3 .2) 19(9 .61
0150 0 (0.0) 206 .4) 486 (14.81
Total
32 31 3.276
Mean dose' 73 .6(<41
94.4 (mg)
107
.1 lOt)
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Table 3
. basel ne Character st cs Accord
ng to Occurrence of Early Death (s18 h)
class fed mechan
sm
of early death between pat
ents w
th
anter or and nonanter or
nfarct
on
. Pump fa
lure was re-
spons ble for death n 28 (65%) of 43 pat ents w th anter or
and Il (55%) of 20 pat ents w th nonanter or nfarct on ;
ventr cular rupture occurred n 7 (16%) of 43 and 3 (15%) of
20 pat ents, respect vely .
T m ng
of beta-blocker therapy. Treatment. results n
the 1,434 pat ents enrolled n the TIMI IIB study were
prev ously reported (14) . Of the 720 pat ents randomly
ass
gned to
mmed
ate ntravenous beta-blocker therapy, 9
(1 .2%) d ed early, 8 of whom rece ved the ass
gned ntrave-
nous metoprolol ; 6 (0 .8%) of the 714 pat ents ass gned to
deferred beta-blocker therapy d ed w th n the 1st 18 h .
Mechan sms of card ac death among pat ents ass
gned to
mmed ate ntravenous beta-blocker therapy ncluded ven-
tr cular rupture
n three (0.4%),
pump fa
lure n fve (0 .7%)
and arrhythm a n one
(0 .1%) . Among pat ents ass gned to
deferred beta-blocker therapy, ventr cular rupture was the
mechan sm of death n two (0.3%), pump fa lure
n one
(0.1%), arrhythm a n two (0.3%) and compl cat ons of
therapy n one (0.1%) .
`H story smles ng for one pat ent who d ed <_ 18 h aflerstudy cnuy.''H story data arc m ss ng far 6 pat ents who
d ed s I8 h after study envy. tCompar restr cted to pat ents w th anter or myocard al nfarct on. CHF =
congest ve heart fa lure: Cl = confdence nterval : MI = myocard al nfarct on : 0-PA = recomb nant t ssue-type
plasm nogen acl vetor. STE = ST segment elevat on : S, = Th rd heart sound.
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D scuss on
As mprovements are made n reperfos on therapy for
pat ents w th acute myocard al nfarct on . the most mpor-
tant ref nements w ll have to be d rected toward the hours
-.-,hen
death
s most frequent
. Our study s the f
rst deta led
exam nat on of the t me of greatest r sk of mortal ty and s
based on prospect vely acqu red data from pat ents rece v ng
thrombolyt c therapy. Our most mportant f nd ngs are that
the greatest mortal ty occurs w
th
n the frst hours after the
onset of acute myocard al nfarct on and treatment w th
thrombolyt c therapy and that mortal ty decreases very
rap
dly thereafter. More than 90% of early deaths occurred
among pat ents n the "not low r sk -" category and >50%
were among pat ents who had already developed cl n cal
s gns of heart fa lure by the t me of n t al evaluat on. Pump
fa lure was the most common mechan sm of death, even
among pat ents who n t ally appeared well compensated
.
Card ac rupture. Card ac rupture occurred n 16% of our
study pat ents who d ed early and was d agnosed more
frequently among pat ents who underwent e ther autopsy or
Death
'18
h
Basel ne Charade t c
yes
IN = 631
1. 19")1
No
IN = 32761
In I%II
Relat ve R sk
199% CD
Male gender
45 171 .41 2.697 182
.31 0.5 (0
.3 .
1 .11
wh te race
55(87 .3)
2 .893 (88 .3)
0 .9 (0 .3 . 2.41
Not low r sk 57190 .51 2 .169 (66 .21 4 .8 (1 .6 . 14.31
Age 070 yr 21 (33 .3) 368 111._'1 3.8 (1 .9 . 7.4)
Pr or MI 16125 .41 450(13.71 2.10.0 . 4.4)
Anter or MI 43168 .21 1 .687 (51 .51 2 .0 (1 .0.4 .0)
Rate, over >113 of lung felds 13 (211 .6) 121 (3 .7) 6 .2 12 .9, 13 .41
Rypnrens nn w sh s nus tvchycard :
17127 .01
17015 .21 6 .2 (3 .1 . 12A)
Atr a) I br llal on en fuller 314
.81
7012 .11 3210
.5 .2 .61
Pulmonary edema
416.41 3010 .91 6 .64 .9. :!3
.1)
Card ogen c shock 13 )20 .6) 37 (1 .11 17 .1 (8.4, 34 .9)
Hemadynam c comprom se
wth.,
shack 22 134 .9) 353)10 .9) 6.1 (3 .0, 12 .5)
('!her r sk factors
H story of
ang
na
•
3303 .2) 1,636 150 .0) 1 .1
(0.6. 2 .21
H story of CHF- 416 .4) 88 42 .71 2.4 (0.7, 9.0!
H story ofhypenens nn' 26 041 .91 1 .253138?1 1210.6. 2 .221
H story of d abetes' 171 227.4) 422113 .91 2 .5 (1 .2. 5 .1)
H story of per pheral vascular d sease' 9114 .51 10617 2) 4.811 .9, 11 .71
H story of smok ng' 32156.11 2.533 177 .3) 0.410.2, 0.81
Current smoker'
17129.81
1 .623 149.5) 0
.4 (02 . 0
.91
Abnormal neck ve n d stens on 11117.51 16315 2) 3.8 0 .7 . 8.9)
Heart block (2nd- or 3rd-degree) 7(11 .11 11813 .6) 3.2(1 .2 .8.8)
Any rules present 2-7142.91 509115.5) 3.9 12.1 . 7.5)
S, present 5 (7.9) 121 13.7) 2 .2 10 .7 . 7.1)
Start of r PA s2 h from symptom onset 14(22_.21 846125.8) 0 .610
.4
.1.81
Anter or MI w th STE a6 leads
Yes 19(44.:1 634137.6)
No 24 ( 55.115 1 .053 162.4) 13 50 .6, 2.911
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Table 4. Cl n cal Observat ons Dur ng tt-PA Infus on Accord ng
to Occurrence of Early Death 1-1B h)
ep Value from test ng assoc at on between early death (w18 N and pa n
response of pat ents w th m ss
ng data ar amb
guous reta n
. n-PA = recom-
b nmll t ssue-type plasm nogen as va or.
surg cal exam nat on of the chest than among pat ents whose
heart was not d rectly exam ned. Although pat ents n whom
ventr
cular rupture was suspected cl n cally may have un-
dergone autopsy more frequently than other pat ents who
d ed, ventr cular rupture was st ll a less common mechan sm
of early death than was pump fa lure even n autopsy cases.
Thus, although some cases of rupture m ght be m sclass f ed
as deaths due to pump fa lure, pump fa lure would st ll be the
most common mechan sm of death. Th s fnd ng has part c-
ular cl n cal mportance, s nce lethal pump fa lure s a
consequence of mass ve myocard al schem a and necros s
and s thus potent ally preventable or remed able f c rcula-
tory support can be prov ded and myocard al necros s l m-
ted . In contrast, ventr cular rupture n the pat ent who has
rece ved throaaboI t c and ant coagulant drugs s more l kely
to be an unpred ctable and rremed able event .
Prev ous stud es, nclud ng the large Internat onal Study
of
Infarct Surv val (ISIS-1) (15 .161, have suggested that early
ventrcular rupture s the most common mechan sm of death
KLEIMAN ET AL.
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Table 5. Mechan sm of Death Accord ng to T me to Death
"Based on the Mortal ty and Morb d ty Class fem
on Comm
ttee ctass
b-
cat on of causes of death accord ng to the follow ng rule : all card ac deaths
w th ventrcular rupture present arc attr buted to rupture: n the absence of
mptur card ac deaths w th pump fa lure present are attr buted m pump
future. CABG = coronary artery bypass graft surgery : Ml = myocard al
nfarct on: PICA = pertulaceous translum tml coronary ang oplasty.
n the early hours after acute myocard al nfarct on. In the
control group of that study . the comb
nat on of ventr cular
rupture and electromechan cal d ssoc at on accounted for
50% of card ac deaths dur ng the 1st day 115,16) . 1n TIMI II,
even among autopsy cases, ventr cular rupture was less
common than pump fa
lure . Th s d fference may be due n
part to the nclus on
of
a larger proport on of pat ents w th
nc
p
ent pump fa lure n TIM( 11 .
In ISIS-I the nc dence of lethal ventr cular rupture was
reduced n pat ents treated w th ntravenous atenolol (15).
Although TIMI IIB results do not document a reduct on
n
the frequency ofcard
ac rupture w th mmed ate ntravenous
beta-blocker therapy among pat ents treated w th threm-
bolyt c agents . they do not exclude that poss b l ty .
Pred ct on of early death. The ab l ty to pred ct early
death on the bas s of cl n cal presentat on was l m ted .
Although the presence of shock was assoc
ated w
th a
26%
rate of early death (13 of 50 pat ents), 22 (6%) of 375 pat ents
w th ev dence of hemodynam c comprom se but w thout
shock exper
enced early death as d
d
28 (1%) of 2,914
pat ents w th m n mal or no hemodynam c comprom se .
Thus . 44% (28 of 63) of the pat ents who d ed early would
have been d ffcult to dent fy, whereas 56% (35 of 63)
could
be cons dered to be at h
gh r sk . The cr ter a of shock or
hemodynam c comprom se would have dent fed 425 (13%)
of t :s 3,339 pat ents n the study who m ght be cons dered
for adjuuct :e or mom aggress ve forms of therapy.
The cl n ced course dur
ng re-PA nfrrsfnn (wh ch was
more frequently nterrupted for pat ents who d ed early than
for others) d d not prov de much further a d . Although only
T me I . Death
Cause
of
Death
,_4 It
M = 32)
=4h-<_ISh
IN = 311
I Is h-42 day,
(N = 10'-1
Card ovascular d sease
30 27
68
Card acd rnase 30 27 64
Fam1 M( 30 57
Qual fy ng b t 30 27 43
Recurrent 0 0 4
Card ac death`
Pomp ra mre 2-1 17 ,
.Arrhythm a
4
4 19
Ventr
cular rupture 4 5
9
Other 0 0 I
Compycal ors 2 04 54
Hemorrhage 3 13
Consequence of CADE 0 I 6
Consequence of PICA 0 0 8
Other 0 0 7
Autopsy obrmned 13 M 38
Death x18 h
Yes
IN = 631
In (911
No
IN =
3 .1_761
In 1911 0 Value
ST segment changes
Normal
zat on only 1(4.81 899!
2 241
0.001
No change reported 49177.81 2,082 163k)
Exacerbat on only 802 71 155 14.71
Both exacerbat on and 3 14 .8, 140(4.31
normal zat on
ra n
rt
r Rel
efofpa n 517 .9) 945 (25 .81 0001'
No change 43168.3) 1 .608 (49.11
Worsen ng 7(31 .1) '-422)7.3(
Absent at Stan
No change 311.81 3 71(0.01
Worsen ng 111 .61 ?9(0.8)
Data m ss ng or amb guous
Mar on dote 2(3.2) '--10.1)
Both rel ef and worsen ng 2 (3.2) 215 (6.51
Rel ef reported when pa n s 111 .61 8 (0. 2_)
ae,cm at n t at on of n-PA
Other cl n
cal obscrval ans
Appearance of new arrhythm as
Yes 48176.21 1.803 155 .01 0.001
No 15 (23.8)
1 .473 (45
.0)
Resolut on of arrhythm as
Yes 416.4) 554(16.91 0.026
No
59193.6) 2.7-12183.11
Blond pressure change
Decrease 44 (69.8) 986 (30.11 0 .001
Increase 314.8) 391 (11 .91 0 .,19
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Table 6. Causes and Mechan
sms of Death Occurr ng <_ 18 h Accord ng to Hemodynam c Status at Study Entry
"Based on the Mortal ty and Morb d ty Class fcut en Comm ttee class f cat on of causes of death, accord ng to the follow ng rule
: all card
ac deaths w
th
ventr
cular rupture present are aur buted to rupture: n the absence of rupture . card ac deaths w th pump fa lure present are aur buted to pump B ltac . ', No, n
card ogen c shock. but present
ng w
th at least one of the follow ngcond l nne: pulmonary edema . mound
. or thrd-degree atr ocoore cularblock. roles over >Il3
of lung felds or hypotens on w th s nus tucltycard a . CABG = coronary m
sty bypass graft surgery.
8 pat ents had rel ef from chest pa n, the pa n d st nctly
worsened n only 10 pat ents. Normal zat on of ST segment
abnormal t es was uncommon among pat ents dy ng early ;
however, th s f nd ng should be v ewed caut ously, s nce
ascerta nment of [h s event requ
red [hat pat ents surv ve
unt l a second electrocard ogram (ECG) could be performed .
The appearance of hypotens on or worsen ng arrhylhm as
was an om nous prognost c s gn, but these events are non-
spec fc features of card ac decompensat on and arrest : the r
or g
ns often cannot be separated from agonal events . How-
ever, of 44 pat ents n whom a decrease n blood pressure
was noted, 43 (98%) surv ved >30 m n and 23 (>50%)
surv ved >2 h after th s determ nat on . Such a fnd ng m ght
allow t me for emergency ang ography and mod fcat on of a
planned management strategy
.
Therapeut c mplcat ons . Further reduct on n mortal ty
among pat ents rece
v
ng thrombolyt c therapy for acute
myocard al nfarct on s poss ble . The most common mech-
an
sm of death was pump fa lure rather than ventr cular
rupture or bleed
ng. Both enzymat c and patholog c stud es
(17,18) of pat ents w th card
ogen c shock have shown that
necros s s a frogress vc rather than an nstantaneous pro-
cess when large areas of myocard um are nvolved. Whether
pump fa lure was a consequence of fa lure to ach eve and
susta n reperfus on or of the nab
l
ty of the dysfunct onal
("stunned") or necrot c myocard um to ma nta n the card ac
output even n the presence of restored anterograde flow s
not known
. If the former, then more v gorous thrombolyt c,
ant thrombot c or ant platelet therapy or mechan
cal revas-
cular zat on would seem to he nd cated . If the latter, tem-
porary mechan cal hemodynam c support m ght be helpful .
G ven that hemodynam c collapse preceded death by >2 h n
>50% of the pat ents who d ed early, aggress ve use of
notrop
c agents or mp.ementat on of such dev ces as n-
traaort
c balloon couuterputsat on or extracorporeal
ventrc-
ular
support m ght be useful
t-, allow
ng t
me for reperfus on
to occur or for dysfunct onal myocard um to recover .
Role of reperfus on. Data from controlled tr als (7 .8) have
suggested that death w th
n the 1st day after myocard al
JACC vet.
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nfarct
on may not be prevented by adm n strat on of throm-
bolyt c agents. Whether th s p);enomenon represents fa lure
of these drugs to produce reperfus on s not known. Other
stud es 119-211 of thrombolyt
c therapy
nd cate that fa
lure
to ach eve and ma nta n patenl:y of the nfarct-related artery
s a strong pred ctor of death both n the hosp tal and after
d scharge . Extens on of th s f nd ng to pat ents who d e early
would requ re rout ne early coronary ang ography, wh ch
was not pan of the TIMI If protocol. Although t would seem
reasonable that early mortal ty s more l kely n pat ents w th
unsuccessful reperfus on therapy, TIMI 11 data do not ad-
dress th s hypothes s. Several reports (22,23) have nd cated
that death from pump fa lure may even follow successful
reperfus on . In an analys s of 500 pat ents undergo ng ang o-
plasly as treatment for acute myocard al
nfarct
on, Ell s et
al. (24) reported that even among th s group, 45% of deaths
occurred w th n the 1st 24 h after card ac catheter zat on .
Although TIM] IIA and other stud es (19,24-26) have shown
the detr
mental effect of the rout ne appl
cat
on of ang o-
plasty after Ihrombolys s . observat ons of favorable exper -
ences w th successful ang oplasty for pat ents n card ogen c
shock (27-30) suggest that select ve appl
cat
on of such
therapy m ght reduce the r sk of early death f appropr ate
cand dates could be dent f ed. Among pat ents present ng
w
th m nor or no hemodynam c comprom se, only 39% of
early deaths were assoc ated w th pump fa lure, and other
causes of death may prove less amenable to ntervent on .
Role of adjunct ve strateg es. Seventy-fve percent of pa-
t ents n our cohort who d ed early had a frst nfarct on,
whereas only 8% had prev ous congest ve heart fa lure .
Rather than represent ng a mor bund group w th preex st ng
severe heart damage, those pat ents who d ed w
th
n the 1st
I8 h are a group who potent ally stand to beneft from
develop ng adjunct ve strateg es.
Our fnd ngs also suggest that further advances n med cal
and hemodynam c support that can be read ly ava lable to all
pat ents may be of use . These
nclude earl er access to
treatment ( nclud ng adm n strat on of thrombolyt c drugs
before the hosp tal stay) and earl er ava lab l ty of hemody-
Hemodynam c Status al Study Entry
Cause of Death -
No
.
or
Deaths
Card ogen c Shock
In
11111
Hemodynam cCompeee scr
In (9,11
No Hemodynam cCamprem se
In 1711
Card ac 57
12192
.31
21195.41 24(85 .7)
Ventr cular mpturo
10
10
.71 1 18,51 8128 .61
Pampfa lure 39 II (84.61 17177 .31
11139
.31
Arrhythm a 8 11511 3 113
.6) 5 (17 .9)
Hemorrhage 1 17 .71 1 1451 3 (10
.71
Compl cat on of CABS 1 (11111 0ln1
1 (3
.6)
Total 61 13 11 01 ) .111 71(101.01 28000.0)
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nam c support for pat ents w th nc p ent pump fa lure . The
f nd ng that a relat vely large proport on of early deaths
occurred before a full dose of rt-PA could be g ven would
support the concept of rap d adm n strat on or "front load-
ng"
of
thrombolyt c therapy (31) .
If early rcperfus on does
l m t ca ly mortal ty, t s conce vable that some early deaths
m ght he averted by the earl er occurrence of reperfus on
that has been reported w th such reg mens. It s also poss
ble
that some of the early deaths occurred n pat ents n whom
reperfus on m ght have succeeded had not the act on of
rt-PA been nterrupted . Th s suggest on should be regarded
as speculat ve, s
nce t s not known whether the early
mortal ty seen n thrombolyt c tr als s preventable by early
reperfus on .
Perhaps a broader
mpl
cat
on of the present study s that
resources should be devoted to mprov ng access to throm-
bolys s. Although the mean t me to treatment n the TIMI II
tr al (8) was relat vely short (2 .6 h) by current standards, and
22% of pat ents w th early death rece ved rt-PA w th n 2 h
after the onset of symptoms . many of the pat ents who d
ed
early had s gns of congest ve heart fa lure when therapy was
n t ated . Thus, for thf . ;e paHrnrs, even "early" therapy was
not early enough.
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